Drugs / CaPre
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01455844 | Sep 2011 → Jun 2014 | hypertriglyceridemia | Grace Therapeutics Inc. | Completed | No outcome recorded |
| Phase 32 trials · 2 met primary | ||||||
| Phase 3 | NCT03361501 | Feb 2018 → Sep 2019 | hypertriglyceridemia | Grace Therapeutics Inc. | Completed | Met primary |
| Phase 3 | NCT03398005 | Jan 2018 → Jul 2019 | hypertriglyceridemia | Grace Therapeutics Inc. | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CaPre | “CaPre™ 2.0g daily for 12 weeks” NCT01455844 ↗ |
| Known as | ω-3-PL/FFA | “OBJECTIVE: To determine the phase 3 efficacy and safety of a naturally derived krill oil with eicosapentaenoic acid and docosahexaenoic acid as both phospholipid esters (PLs)...” PMID 34989797 ↗ Jan 2022 |
| Modality | Other / unclassified | “a novel krill oil-derived ω-3 formulation” PMID 34989797 ↗ Jan 2022 |
| Route | Oral | “4 x 1 g capsules administered orally once daily for 26 weeks” NCT03361501 ↗ |